Novartis (NVS) is making a compelling case for its leadership in rare kidney diseases, a narrative significantly bolstered by the new data presented at the European Renal Association (ERA) Congress, which concluded today, May 25, 2026. The company unveiled 15 abstracts from its kidney portfolio, reinforcing the scientific understanding of these complex conditions and showcasing the strength of its therapeutic offerings. This comprehensive data dump, particularly for its key assets Fabhalta (iptacopan) and atrasentan (marketed as Vanrafia in some regions), suggests a strong bullish outlook for Novartis's renal segment, which is poised to become a significant growth driver for the pharmaceutical giant.
The strategic importance of this portfolio cannot be overstated. With a market capitalization of $290.05 billion and shares trading at $152.01 as of May 22, 2026, Novartis is a behemoth, but sustained growth relies on innovative pipeline execution. The kidney disease market, particularly for rare conditions like IgA nephropathy (IgAN) and C3 glomerulopathy (C3G), represents a substantial unmet medical need and a multi-billion dollar opportunity. Novartis's multi-asset strategy, targeting different pathways implicated in kidney damage, offers a differentiated approach compared to rivals and could capture a significant share of this evolving market.
The company's commitment to this therapeutic area is evident in its long-standing history in nephrology, dating back over 40 years with cyclosporine. Today, Novartis aims to transform care beyond transplantation, focusing on slowing disease progression and extending dialysis-free life. This ambition is now being realized through its advanced pipeline, with Fabhalta, atrasentan, and zigakibart forming a powerful trio designed to address the heterogeneity of kidney diseases. The ERA 2026 presentations provided critical updates that will inform investor sentiment and future revenue projections for these key drugs.
Fabhalta (iptacopan) continues to be a cornerstone of Novartis's rare kidney disease strategy, with new data at ERA 2026 further solidifying its potential. The drug, an oral Factor B inhibitor of the alternative complement pathway, has already secured accelerated FDA approval in 2024 for IgAN, based on initial data. More recently, in October 2025, Novartis reported final results from the Phase III APPLAUSE-IgAN study, demonstrating that Fabhalta significantly slowed the decline of kidney function in IgAN patients over two years. This pivotal finding, which showed a 44% reduction in proteinuria over nine months compared to a mere 9% with placebo (p<0.0001), is crucial for securing full, traditional FDA approval, which Novartis plans to seek in 2026.
Beyond IgAN, Fabhalta's utility in C3 glomerulopathy (C3G) also received significant attention. At the ERA Congress in May 2024, Novartis presented compelling Phase III APPEAR-C3G study data, revealing a statistically significant 35.1% reduction in proteinuria at six months compared to placebo (p=0.0014). This is particularly impactful as C3G is an ultra-rare, progressive kidney disease with no currently approved treatments, where approximately 50% of patients progress to kidney failure within 10 years. The favorable safety profile observed in both trials, with no new safety signals, further enhances Fabhalta's appeal and broadens its potential market.
Novartis has high expectations for Fabhalta, earmarking it as a potential $3 billion drug. Its versatility is being explored across several other rare conditions, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and lupus nephritis (LN). An FDA filing for C3 glomerulopathy is anticipated by the end of 2025, which, if successful, would significantly expand Fabhalta's commercial footprint. The drug's initial approval for paroxysmal nocturnal hemoglobinuria (PNH) in December 2023 (FDA) and May 2024 (EMA) has already established its safety and efficacy, providing a strong foundation for these additional indications.
Atrasentan, marketed as Vanrafia in some regions, represents another critical asset in Novartis's burgeoning kidney portfolio, particularly for IgA nephropathy (IgAN). The drug, an investigational oral selective endothelin A (ETA) receptor antagonist, was a key acquisition from Chinook Therapeutics in 2023, a deal valued at up to £2.5 billion. This strategic move immediately bolstered Novartis's late-stage pipeline with a promising therapy that targets a distinct mechanism of IgAN progression.
The Phase III ALIGN study has been central to atrasentan's development. An interim analysis presented at the ERA Congress in May 2024 demonstrated a statistically significant 36.1% reduction in proteinuria at 36 weeks compared to placebo plus supportive care (p<0.0001). This early success was a strong indicator of the drug's efficacy. Building on this, Vanrafia received accelerated approval in the United States and China in 2025 for reducing proteinuria in adults with IgAN, a significant milestone.
Further positive data emerged in February 2026, when Novartis reported clinically meaningful benefits in estimated glomerular filtration rate (eGFR) change from baseline at week 132, showing a 2.59 ml/min/1.73m² difference compared to placebo. This eGFR data, a direct measure of kidney function, is critical for gaining full, traditional approval, which Novartis plans to seek in 2026. The final analysis of the ALIGN study, including eGFR changes at 136 weeks, is also expected in 2026. Atrasentan's mechanism, by targeting the endothelin A receptor, offers a complementary approach to Fabhalta, allowing Novartis to address a broader spectrum of IgAN patients and compete effectively against rivals like Travere's FILSPARI.
Beyond Fabhalta and atrasentan, Novartis is strategically advancing zigakibart, a subcutaneous anti-APRIL monoclonal antibody, as the third pillar of its IgAN portfolio. This multi-pronged approach underscores Novartis's commitment to addressing the complex and heterogeneous nature of IgAN, a disease where up to 30% of patients with persistent proteinuria can progress to kidney failure within 10 years. Zigakibart's distinct mechanism of action, targeting the production of abnormal galactose-deficient IgA, offers a novel therapeutic pathway that could benefit patients unresponsive to other treatments.
Zigakibart entered Phase III development in July 2023, following promising interim Phase I/II data that showed significant reductions in proteinuria versus baseline. The Phase III APPLAUSE-IgAN trial is a randomized, double-blind, parallel-group, placebo-controlled study with approximately 470 participants, evaluating 200 mg oral doses of Fabhalta twice daily. The inclusion of zigakibart in the pipeline, also acquired through the Chinook Therapeutics deal, highlights Novartis's foresight in building a comprehensive suite of therapies. This ensures that the company can cater to various disease presentations and patient profiles, maximizing its market penetration in the IgAN space.
The development of zigakibart, alongside Fabhalta and atrasentan, positions Novartis with a unique advantage. While Fabhalta targets the complement pathway and atrasentan focuses on endothelin A receptors, zigakibart directly intervenes in the immune-mediated drivers of IgAN. This diversity in therapeutic mechanisms is crucial in a competitive landscape where other companies like Biogen, Vertex, Vera Therapeutics, and Otsuka Pharmaceutical are also advancing their own IgAN drugs. By offering multiple, differentiated options, Novartis aims to provide personalized treatment strategies, ultimately improving patient outcomes and securing a dominant position in the rare kidney disease market.
The rare kidney disease market, particularly for IgA nephropathy (IgAN), is rapidly becoming a hotbed of innovation and competition. While Novartis has made significant strides with Fabhalta and atrasentan, the landscape is crowded with rivals. Otsuka Pharmaceutical, for instance, has already filed for FDA approval of its drug, sibeprenlimab, and could secure approval within weeks. Other players like Vera Therapeutics, Biogen, and Vertex have also invested heavily in IgAN drugs, signaling intense competition for market share. This dynamic environment means that while Novartis's recent data is positive, sustained success will depend on effective commercialization, payer collaboration, and continued pipeline advancements.
For investors, Novartis's strong performance in the kidney portfolio offers a compelling growth narrative within its broader innovative medicines strategy. The company's recent financial results, including better-than-expected first-quarter earnings and revenues, indicate robust performance across key brands. The strategic spin-off of Sandoz in 2023 has allowed Novartis to focus on core therapeutic areas, including cardiovascular, renal, and metabolic diseases. This sharpened focus, combined with successful acquisitions like Chinook Therapeutics and MorphoSys (for €68 per share in April 2024), underscores a proactive strategy to enhance its pipeline and drive future profitability.
Novartis currently holds a Zacks Rank #3 (Hold), reflecting a balanced view of its near-term prospects. However, the long-term outlook for its kidney portfolio, particularly with the potential for traditional approvals for Fabhalta and atrasentan in 2026, suggests significant upside. The company's ability to differentiate its offerings through multiple mechanisms of action, coupled with its commitment to patient access programs, will be critical in navigating the competitive landscape. Investors should closely monitor the upcoming regulatory decisions and commercial launches for these key assets, as they will be pivotal in determining the extent of Novartis's market leadership in rare kidney diseases.
Novartis's recent data at ERA 2026 firmly establishes its kidney portfolio as a significant growth engine, with Fabhalta and atrasentan poised for broader market impact. The company's multi-pronged approach, featuring three distinct mechanisms of action, provides a robust strategy to address the diverse needs of patients with IgAN and C3G. As regulatory submissions for traditional approvals progress in 2026, these innovative therapies are expected to drive substantial revenue growth and solidify Novartis's leadership in the evolving rare kidney disease market.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
